Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Gyre Therapeutics, Inc. reported revenue of $117M, up 10.2% year over year. Operating margin was 9.9% and net margin 8.5%, on a free-cash-flow margin of -0.2% with capital expenditure at 1.0% of revenue. Every figure is computed directly from GYRE's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $117M | 9.9% | 8.5% |
| FY2024 | $106M | 15.3% | 16.9% |
| FY2023 | $113M | -59.3% | -75.3% |
| FY2022 | $102M | 9.0% | 4.2% |
| FY2021 | $7M | -1197.8% | -1198.3% |
How does GYRE compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.